HIGHLIGHTS Geological and geochemical sampling campaigns designed to guide effective targeting for drill programs in Q2 2025 ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Medicare, the government-backed program for adults aged 65 and older and those with disabilities, only covers the use of ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Data by YCharts Semaglutide is the active ingredient in Novo Nordisk's weight loss drug Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand ...

Locality Bank officially completed its de novo period on January 12, 2025, marking a significant milestone and the end of the initial three-year supervisory phase for newly chartered banks, ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

Here are five things to know about the company's de novo strategy: 1. USPI added nearly 70 ASCs in 2024, remaining "very active in both [mergers and acquisitions] and de novo development." The company ...